A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening
Blood-based colorectal cancer screening makes the distinction between cancer and precancer endpoints especially clear.
What the paper explores
The ECLIPSE study evaluated a cell-free DNA blood test in a screening-eligible population against colonoscopy. The reported performance differed substantially for colorectal cancer and advanced precancerous lesions, showing why these outcomes should be presented separately rather than combined into a single claim.
How to interpret the evidence
Diagnostic accuracy alone does not establish improved screening adherence or reduced mortality. The study’s findings apply to the assessed assay and population.
Questions for MedTech teams
Define clinically meaningful endpoints in advance. A test’s ability to identify existing cancer and its ability to detect precursors answer different screening questions.
Sources & further reading
Read original paperDOI: 10.1056/NEJMoa2304714
Bibliographic record and abstract on PubMedThis is a short editorial reading note on external research. The original research is attributed to its authors and does not represent an HMC study, product validation or regulatory determination.
